Kappa Bioscience
Oslo, Oslo, Norway
About Kappa Bioscience
Kappa Bioscience is the pioneer in the development and production of the only synthetic and biologically active all-trans menaquinone-7 (vitamin K2 MK-7), marketed under the K2VITAL brand name. Kappa’s innovation of MK-7 synthesis marks the commercial milestone where this fat-soluble vitamin can begin to attain widespread consumer adoption. Effective synthesis production drives scalability, price reduction, and a secure supply chain - with unmatched ingredient purity and documentation. Combined with other Kappa innovations such as the patented DELTA microencapsulation process, which provides K2 stability in mineral formulations, K2VITAL offers brands and manufacturers a path to broader market segments. Kappa Ingredients GmbH, a wholly-owned division of Kappa Bioscience, manages global sales of the K2VITAL and other product lines directly and through a network of global distributors. Kappa Ingredients GmbH, a wholly-owned division of Kappa Bioscience, manages global sales of the K2VITAL and other product lines - Ingredients and services related to Bones, Joints, and Cardiovascular Health - directly and through a network of global distributors. The main products are Vitamin K2 - K2VITAL, Calcified Atlantic Seaweed, and The Bone Health Triangle.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Funding stage: M&A
- Last round: Series Unknown (Jan 2009)
- Website: kappabio.com
- Phone: +49 40 6094087 0
Industries & Categories
Biotechnology, Life Science, Pharmaceutical, Wellness
Social Profiles
Canonical: https://fsome.com/organization/kappa-bioscience-2545226 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.